These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38409605)

  • 1. Sclerostin secreted from bone mediates cognitive decline in the brains of aged and Alzheimer's disease mice.
    Nat Metab; 2024 Mar; 6(3):394-395. PubMed ID: 38409605
    [No Abstract]   [Full Text] [Related]  

  • 2. Rejuvenating the blood and bone marrow to slow aging-associated cognitive decline and Alzheimer's disease.
    Kang S; Moser VA; Svendsen CN; Goodridge HS
    Commun Biol; 2020 Feb; 3(1):69. PubMed ID: 32054965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Awareness of memory deficits in subjective cognitive decline, mild cognitive impairment, Alzheimer's disease and Parkinson's disease.
    Lautenschlager NT
    Int Psychogeriatr; 2015 Mar; 27(3):355-6. PubMed ID: 25640918
    [No Abstract]   [Full Text] [Related]  

  • 5. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alexithymia in people with subjective cognitive decline, mild cognitive impairment, and mild Alzheimer's disease.
    Yuruyen M; Akcan FE; Batun GC; Gultekin G; Toprak M; Yavuzer H; Emul M
    Aging Clin Exp Res; 2017 Dec; 29(6):1105-1111. PubMed ID: 28110464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Koro Delusion in Mild Cognitive Impairment Due to Alzheimer's Disease.
    Tau M; Masurkar AV
    J Neuropsychiatry Clin Neurosci; 2020; 32(2):204-206. PubMed ID: 31530117
    [No Abstract]   [Full Text] [Related]  

  • 9. Longitudinal Cognitive Decline in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease.
    Lim YY; Kong J; Maruff P; Jaeger J; Huang E; Ratti E
    J Prev Alzheimers Dis; 2022; 9(1):178-183. PubMed ID: 35098989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3.
    Liu-Seifert H; Siemers E; Sundell K; Mynderse M; Cummings J; Mohs R; Aisen P
    J Prev Alzheimers Dis; 2018; 5(3):184-187. PubMed ID: 29972211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring decline in prodromal AD: a pike to hike.
    Molinuevo JL
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):358. PubMed ID: 24013275
    [No Abstract]   [Full Text] [Related]  

  • 13. Cholinergic white matter pathways along the Alzheimer's disease continuum.
    Nemy M; Dyrba M; Brosseron F; Buerger K; Dechent P; Dobisch L; Ewers M; Fliessbach K; Glanz W; Goerss D; Heneka MT; Hetzer S; Incesoy EI; Janowitz D; Kilimann I; Laske C; Maier F; Munk MH; Perneczky R; Peters O; Preis L; Priller J; Rauchmann BS; Röske S; Roy N; Scheffler K; Schneider A; Schott BH; Spottke A; Spruth EJ; Wagner M; Wiltfang J; Yakupov R; Eriksdotter M; Westman E; Stepankova O; Vyslouzilova L; Düzel E; Jessen F; Teipel SJ; Ferreira D
    Brain; 2023 May; 146(5):2075-2088. PubMed ID: 36288546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling Decline in Cognition to Decline in Function in Alzheimer's Disease.
    Karcher H; Savelieva M; Qi L; Hummel N; Caputo A; Risson V; Capkun G; Alzheimer's Disease Neuroimaging Initiative
    Curr Alzheimer Res; 2020; 17(7):635-657. PubMed ID: 33032508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for Alzheimer's disease beyond amyloid and tau.
    Zetterberg H; Schott JM
    Nat Med; 2019 Feb; 25(2):201-203. PubMed ID: 30728536
    [No Abstract]   [Full Text] [Related]  

  • 16. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.
    Bilello M; Doshi J; Nabavizadeh SA; Toledo JB; Erus G; Xie SX; Trojanowski JQ; Han X; Davatzikos C
    J Alzheimers Dis; 2015; 48(4):987-94. PubMed ID: 26402108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subjective cognitive decline: preclinical manifestation of Alzheimer's disease.
    Lin Y; Shan PY; Jiang WJ; Sheng C; Ma L
    Neurol Sci; 2019 Jan; 40(1):41-49. PubMed ID: 30397816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors underlying cognitive decline in old age and Alzheimer's disease: the role of the hippocampus.
    Jaroudi W; Garami J; Garrido S; Hornberger M; Keri S; Moustafa AA
    Rev Neurosci; 2017 Oct; 28(7):705-714. PubMed ID: 28422707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olfactory Dysfunction Is Already Present with Subjective Cognitive Decline and Deepens with Disease Severity in the Alzheimer's Disease Spectrum.
    Wang Q; Chen B; Zhong X; Zhou H; Zhang M; Mai N; Wu Z; Huang X; Haehner A; Chen X; Auber LA; Peng Q; Hummel T; Ning Y
    J Alzheimers Dis; 2021; 79(2):585-595. PubMed ID: 33361601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.